We review the 5-year update of CheckMate 227 and the POSEIDON to generate the hypothesis that CLTA-4 inhibition has a role in PD-L1 negative metastatic NSCLC.

CM 227 update: https://pubmed.ncbi.nlm.nih.gov/?term=36223558
POSEIDON: https://pubmed.ncbi.nlm.nih.gov/?term=36327426
Editorial: https://pubmed.ncbi.nlm.nih.gov/?term=36331243

Mirvetuximab Soravtansine

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients we cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.